Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma

References

• Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–958. doi:10.1016/j.jaci.2017.03.050
   PubMed Web of Science ®Google Scholar
• Niimi A. Redefining “one airway, one disease”: broader classification considering specific pathophysiology and treatment. Respir Invest. 2021;59(5):573–575. doi:10.1016/j.resinv.2021.04.008
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Tamura G, Akasaka T, et al. Analysis of the comorbidity of bronchial asthma and allergic rhinitis by questionnaire in 10,009 patients. Allergol Int. 2009;58:55–61. doi:10.2332/allergolint.08-OA-0004
   PubMedGoogle Scholar
• Ohta K, Bousquet PJ, Aizawa H, et al. Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. Allergy. 2011;66:1287–1295. doi:10.1111/j.1398-9995.2011.02676.x
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, et al. Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma. Respiration. 2014;87:211–218. doi:10.1159/000355706
   PubMed Web of Science ®Google Scholar
• Burgess JA, Walters EH, Byrnes GB, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120:863–869. doi:10.1016/j.jaci.2007.07.020
   PubMed Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372:1049–1057. doi:10.1016/S0140-6736(08)61446-4
   PubMed Web of Science ®Google Scholar
• Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy. 2005;35:723–727. doi:10.1111/j.1365-2222.2005.02251.x
   PubMed Web of Science ®Google Scholar
• Price D, Zhang Q, Kocevar VS, Yin DD, Thomas M. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy. 2005;35:282–287. doi:10.1111/j.1365-2222.2005.02182.x
   PubMed Web of Science ®Google Scholar
• Halpern MT, Schmier JK, Richner R, Guo C, Togias A. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma. 2004;41:117–126. doi:10.1081/JAS-120026069
   PubMed Web of Science ®Google Scholar
• Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013;68:569–579. doi:10.1111/all.12124
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107:469–476. doi:10.1067/mai.2001.113046
   PubMed Web of Science ®Google Scholar
• Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol. 1992;89:611–618. doi:10.1016/0091-6749(92)90329-Z
   PubMed Web of Science ®Google Scholar
• Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergol Int. 2020;69(2):167–177. doi:10.1016/j.alit.2020.01.004
   PubMed Web of Science ®Google Scholar
• Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55:379–386. doi:10.2332/allergolint.55.379
   PubMedGoogle Scholar
• Nagakura T, Ogino S, Okubo K, Sato N, Takahashi M, Ishikawa T. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy. 2008;38:329–337. doi:10.1111/j.1365-2222.2007.02894.x
   PubMed Web of Science ®Google Scholar
• Okubo K, Okano M, Sato N, et al. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. J Allergy Clin Immunol Pract. 2020;8:3130–3140.e2. doi:10.1016/j.jaip.2020.04.068
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205:17–35. doi:10.1164/rccm.202109-2205PP
   PubMed Web of Science ®Google Scholar
• Okubo K, Kurono Y, Ichimura K, et al. Japanese guidelines for allergic rhinitis 2020. Allergol Int. 2020;69:331–345. doi:10.1016/j.alit.2020.04.001
   PubMed Web of Science ®Google Scholar
• Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan. Respir Med. 2018;141:56–63. doi:10.1016/j.rmed.2018.06.021
   PubMed Web of Science ®Google Scholar
• Takemura M, Niimi A, Matsumoto H, et al. Atopic features of cough variant asthma and classic asthma with wheezing. Clin Exp Allergy. 2007;(37):1833–1839. doi:10.1111/j.1365-2222.2007.02848.x
   PubMedGoogle Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66:671–678. doi:10.1111/j.1398-9995.2010.02522.x
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28–35. doi:10.1378/chest.10-1194
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2021;59:501–510. doi:10.4193/Rhin21.159
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5:1362–1370.e2. doi:10.1016/j.jaip.2017.02.002
   PubMed Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021;9:2702–2714. doi:10.1016/j.jaip.2021.01.011
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–811. doi:10.1164/rccm.201208-1414OC
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71:1472–1479. doi:10.1111/all.12922
   PubMed Web of Science ®Google Scholar
• Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51:1702523. doi:10.1183/13993003.02523-2017
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, A prospective real-world study. J Allergy Clin Immunol Pract. 2019;7:156–164.e1. doi:10.1016/j.jaip.2018.04.043
   PubMed Web of Science ®Google Scholar
• Domingo C, Pomares X, Navarro A, et al. Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma caused by either seasonal or perennial allergens: a pilot study. Int J Mol Sci. 2017;18:521. doi:10.3390/ijms18030521
   PubMed Web of Science ®Google Scholar
• Mizuma H, Tanaka A, Uchida Y, et al. Influence of omalizumab on allergen-specific ige in patients with adult asthma. Int Arch Allergy Immunol. 2015;168:165–172. doi:10.1159/000442668
   PubMed Web of Science ®Google Scholar
• Vaník P, Novosad J, Kirchnerová O, Krčmová I, Teřl M. Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry. Allergy Asthma Clin Immunol. 2020;16:81. doi:10.1186/s13223-020-00479-1
   PubMed Web of Science ®Google Scholar
• Soong W, Yoo B, Pazwash H, Holweg CTJ, Casale TB. Omalizumab response in patients with asthma by number and type of allergen. Ann Allergy Asthma Immunol. 2021;127:223–231. doi:10.1016/j.anai.2021.04.002
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, Blogg M, Jimenez P, Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64:1780–1787. doi:10.1111/j.1398-9995.2009.02119.x
   PubMedGoogle Scholar
• Lombardi C, Savi E, Ridolo E, Passalacqua G, Canonica GW. Is allergic sensitization relevant in severe asthma? Which allergens may be culprit? World Allergy Organ J. 2017;10:2. doi:10.1186/s40413-016-0138-8
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Milanese M, et al. Factors reducing omalizumab response in severe asthma. Eur J Intern Med. 2018;52:78–85. doi:10.1016/j.ejim.2018.01.026
   PubMed Web of Science ®Google Scholar